Table 2.

Current Clinical Trials with PLK Inhibitors

Drug	Selectivity	Sponsor	NCT ID	Phase	Disease	Combination	Status	Reference
BI-2536	Pan PLK	Boehringer Ingelheim	NCT00701766	1	AML	None	Completed	50
CFI-400945	PLK4	University Health Network Toronto, Canada	NCT03187288	1	AML, MDS	None	Recruiting	156
CFI-400945	PLK4	Treadwell Therapeutics, Inc	NCT04730258	1/2	AML, MDS, CMML	Azacitidine or decitabine	Not yet recruiting	157
CYC140	PLK1	Cyclacel Pharmaceuticals	NCT03884329	1	AML, ALL, MDS, CML, CLL	None	Recruiting
Onvansertib	PLK1	Cardiff Oncology	NCT03303339	1/2	AML	LDAC or decitabine	Active, not recruiting	66, 67
Rigosertib	PLK/RAF/PI3K inhibitor	Onconova Therapuetics	NCT01926587	1/2	AML, MDS, CMML	Azacitidine	Active, not recruiting	158
Rigosertib	PLK/RAF/PI3K inhibitor	Onconova Therapuetics	NCT00854646	1	AML, MDS, CMML, CML, CLL	None	Completed	159
Rigosertib	PLK/RAF/PI3K inhibitor	Onconova Therapuetics	NCT01241500	3	MDS	None	Completed	160
Rigosertib	PLK/RAF/PI3K inhibitor	Onconova Therapuetics	NCT02562443	3	MDS	None	Active, not recruiting
Volasertib	Pan PLK	Boehringer Ingelheim	NCT00804856	1	AML	LDAC	Active, not recruiting	57
Volasertib	Pan PLK	Boehringer Ingelheim	NCT00804856	2	AML	LDAC	Active, not recruiting	58
Volasertib	Pan PLK	Boehringer Ingelheim	NCT01721876	3	AML	LDAC	Active, not recruiting	59
Volasertib	Pan PLK	Boehringer Ingelheim	NCT02003573	1	AML	Decitabine	Terminated	60
Volasertib	Pan PLK	Boehringer Ingelheim	NCT02721875	1	MDS	Azacitidine	Terminated

Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; LDAC, low-dose cytarabine; MDS, myelodysplastic syndrome; PLK, polo-like kinase